Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
ISSN: 2471-9552
Nadica Trajkovska
Medical Faculty, Ss. Cyril and Methodius University - Skopje
Posters & Accepted Abstracts: Immunotherapy (Los Angel)
Statement of the Problem: Chromogranin A (CgA) or parathyroid secretory protein 1 is a member of the granin family of neuroendocrine secretory proteins and is located in the secretory vesicles of neurons and endocrine cells. We evaluated the pattern of Chromogranin A (CgA) plasma levels in a large number of patients diagnosed with neuro-endocrine tumors (NETs), a series of patients with chronic diarrhea or colitis and patients suspected of having some NET. Patients and methods: Seventy nine patients��? Chromogranin A levels were measured in a total of 106 specimens, from which 20 patients with non-tumor diagnosis, 18 patients with benign tumors, 17 patients with malignant tumors and 29 patients were suspected of having a NET. The CgA plasma levels were measured with the Dako Chromogranin A Elisa Kit. Results: From 17 patients with malignant NET in a total of 29 measurements, 25 came positive for elevated CgA plasma levels with an average value of 230, 24 U/L. From 18 patients with benign NET in a total of 22 measurements, 15 came positive with an average value of 27, 45 U/L. From 20 patients with a non-tumor diagnosis and in a total of 25 measurements, 19 came positive with an average value of 82, 11 U/L. CgA plasma levels were significantly higher in patients diagnosed with a malignant NET compared to benign NETs (P<0,001). CgA plasma levels were higher in patients with a current non- tumor diagnosis compared to benign NET (P<0,001). Conclusion: Our study confirms the high sensitivity and specificity of CgA in diagnosing neuro-endocrine tumors. It is necessary to use a cutoff range of 25 -30 U/L to obtain a high specificity in diagnosing benign NET and a cutoff range of 185 - 275 U/L for malignant NETs with the aim to exclude patients in whom CgA levels were elevated due to a non-tumor disease or pharmaceutical treatment.
Email: nadica.trajkovska@gmai.com